|
1
|
Jacobs IJ and Menon U: Progress and
challenges in screening for early detection of ovarian cancer. Mol
Cell Proteomics. 3:355–366. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Agarwal R and Kaye SB: Ovarian cancer:
Strategies for overcoming resistance to chemotherapy. Nat Rev
Cancer. 3:502–516. 2003. View
Article : Google Scholar : PubMed/NCBI
|
|
3
|
American Cancer Society. Ovarian Cancer
Key Statistics. http://www.cancer.org/cancer/ovariancancer/index.
2014
|
|
4
|
Foo LY, Lu Y, Howell AB and Vorsa N:
A-Type proanthocyanidin trimers from cranberry that inhibit
adherence of uropathogenic P-fimbriated Escherichia coli. J Nat
Prod. 63:1225–1228. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Seeram NP, Adams LS, Hardy ML and Heber D:
Total cranberry extract versus its phytochemical constituents:
Antiproliferative and synergistic effects against human tumor cell
lines. J Agric Food Chem. 52:2512–2517. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Neto CC: Cranberry and its phytochemicals:
A review of in vitro anticancer studies. J Nutr. 137(Suppl):
S186–S193. 2007.
|
|
7
|
Neto CC, Krueger CG, Lamoureaux TL, et al:
MALDI-TOFMS characterization of proanthocyanidins from cranberry
fruit (Vaccinium macrocarpon) that inhibit tumor cell growth and
matrix metalloproteinase expression in vitro. J Sci Food Agric.
86:18–25. 2006. View Article : Google Scholar
|
|
8
|
Ferguson PJ, Kurowska E, Freeman DJ,
Chambers AF and Koropatnick DJ: A flavonoid fraction from cranberry
extract inhibits proliferation of human tumor cell lines. J Nutr.
134:1529–1535. 2004.PubMed/NCBI
|
|
9
|
Singh AP, Singh RK, Kim KK, Satyan KS,
Nussbaum R, Torres M, Brard L and Vorsa N: Cranberry
proanthocyanidins are cytotoxic to human cancer cells and sensitize
platinum-resistant ovarian cancer cells to paraplatin. Phytother
Res. 23:1066–1074. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kim KK, Singh AP, Singh RK, Demartino A,
Brard L, Vorsa N, Lange TS and Moore RG: Anti-angiogenic activity
of cranberry proanthocyanidins and cytotoxic properties in ovarian
cancer cells. Int J Oncol. 40:227–235. 2012.
|
|
11
|
Singh AP, Lange TS, Kim KK, Brard L, Horan
T, Moore RG, Vorsa N and Singh RK: Purified cranberry
proanthocyanidines (PAC-1A) cause pro-apoptotic signaling, ROS
generation, cyclophosphamide retention and cytotoxicity in
high-risk neuroblastoma cells. Int J Oncol. 40:99–108. 2012.
|
|
12
|
Vvedenskaya IO, Rosen RT, Guido JE,
Russell DJ, Mills KA and Vorsa N: Characterization of flavonols in
cranberry (Vaccinium macrocarpon) powder. J Agric Food Chem.
52:188–195. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Wilson T, Singh AP, Vorsa N, Goettl CD,
Kittleson KM, Roe CM, Kastello GM and Ragsdale FR: Human glycemic
response and phenolic content of unsweetened cranberry juice. J Med
Food. 11:46–54. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Singh AP, Wilson T, Kalk AJ, Cheong J and
Vorsa N: Isolation of specific cranberry flavonoids for biological
activity assessment. Food Chem. 116:963–968. 2009. View Article : Google Scholar :
|
|
15
|
Nicholson RI, Gee JMW and Harper ME: EGFR
and cancer prognosis. Eur J Cancer. 37(Suppl 4): S9–S15. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Schilder RJ, Hall L, Monks A, Handel LM,
Fornace AJ Jr, Ozols RF, Fojo AT and Hamilton TC: Metallothionein
gene expression and resistance to cisplatin in human ovarian
cancer. Int J Cancer. 45:416–422. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Bacchetti S and Graham F: Inhibition of
cell-proliferation by an adenovirus vector expressing the human
wild type-p53 protein. Int J Oncol. 3:781–788. 1993.PubMed/NCBI
|
|
18
|
Anderson NG, Ahmad T, Chan K, Dobson R and
Bundred NJ: ZD1839 (Iressa), a novel epidermal growth factor
receptor (EGFR) tyrosine kinase inhibitor, potently inhibits the
growth of EGFR-positive cancer cell lines with or without erbB2
overexpression. Int J Cancer. 94:774–782. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Shen SC, Chen YC, Hsu FL and Lee WR:
Differential apoptosis-inducing effect of quercetin and its
glycosides in human promyeloleukemic HL-60 cells by alternative
activation of the caspase 3 cascade. J Cell Biochem. 89:1044–1055.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Murota K, Shimizu S, Chujo H, Moon JH and
Terao J: Efficiency of absorption and metabolic conversion of
quercetin and its glucosides in human intestinal cell line Caco-2.
Arch Biochem Biophys. 384:391–397. 2000. View Article : Google Scholar
|
|
21
|
Yarden Y: The EGFR family and its ligands
in human cancer. signalling mechanisms and therapeutic
opportunities. Eur J Cancer. 37(Suppl 4): S3–S8. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Sun Q, Prasad R, Rosenthal E and Katiyar
SK: Grape seed proanthocyanidins inhibit the invasiveness of human
HNSCC cells by targeting EGFR and reversing the
epithelial-to-mesenchymal transition. PLoS One. 7:e31093. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Rodemann HP, Dittmann K and Toulany M:
Radiation-induced EGFR-signaling and control of DNA-damage repair.
Int J Radiat Biol. 83:781–791. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Wang SC and Hung MC: Nuclear translocation
of the epidermal growth factor receptor family membrane tyrosine
kinase receptors. Clin Cancer Res. 15:6484–6489. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Liccardi G, Hartley JA and Hochhauser D:
EGFR nuclear translocation modulates DNA repair following cisplatin
and ionizing radiation treatment. Cancer Res. 71:1103–1114. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Jamieson ER and Lippard SJ: Structure,
recognition, and processing of cisplatin-DNA adducts. Chem Rev.
99:2467–2498. 1999. View Article : Google Scholar
|
|
27
|
Jung Y and Lippard SJ: Direct cellular
responses to platinum-induced DNA damage. Chem Rev. 107:1387–1407.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Stokoe D, Macdonald SG, Cadwallader K,
Symons M and Hancock JF: Activation of Raf as a result of
recruitment to the plasma membrane. Science. 264:1463–1467. 1994.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Roberts PJ and Der CJ: Targeting the
Raf-MEK-ERK mitogen-activated protein kinase cascade for the
treatment of cancer. Oncogene. 26:3291–3310. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Chang F, Steelman LS, Shelton JG, Lee JT,
Navolanic PM, Blalock WL, Franklin R and McCubrey JA: Regulation of
cell cycle progression and apoptosis by the Ras/Raf/MEK/ERK pathway
(Review). Int J Oncol. 22:469–480. 2003.PubMed/NCBI
|
|
31
|
Hans F and Dimitrov S: Histone H3
phosphorylation and cell division. Oncogene. 20:3021–3027. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Chadee DN, Hendzel MJ, Tylipski CP, Allis
CD, Bazett-Jones DP, Wright JA and Davie JR: Increased Ser-10
phosphorylation of histone H3 in mitogen-stimulated and
oncogene-transformed mouse fibroblasts. J Biol Chem.
274:24914–24920. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Agarwal ML, Agarwal A, Taylor WR and Stark
GR: p53 controls both the G2/M and the G1 cell cycle checkpoints
and mediates reversible growth arrest in human fibroblasts. Proc
Natl Acad Sci USA. 92:8493–8497. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Ciccarelli C, Marampon F, Scoglio A, Mauro
A, Giacinti C, De Cesaris P and Zani BM: p21WAF1
expression induced by MEK/ERK pathway activation or inhibition
correlates with growth arrest, myogenic differentiation and
onco-phenotype reversal in rhabdomyosarcoma cells. Mol Cancer.
4:41. 2005. View Article : Google Scholar
|
|
35
|
Harper JW, Adami GR, Wei N, Keyomarsi K
and Elledge SJ: The p21 Cdk-interacting protein Cip1 is a potent
inhibitor of G1 cyclin-dependent kinases. Cell. 75:805–816. 1993.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Vermeulen K, Van Bockstaele DR and
Berneman ZN: The cell cycle: A review of regulation, deregulation
and therapeutic targets in cancer. Cell Prolif. 36:131–149. 2003.
View Article : Google Scholar : PubMed/NCBI
|
